The DOI matches its Crossref record; the references it cites are not checked yet.
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
Abstract
Background New pharmacological therapies for the treatment of cardiovascular disease (CVD) have emerged in recent years. The high rates of CVD and the need for long-term treatment to decrease risk factors makes cost-effectiveness crucial for their successful long-term implementation. Objective This study assessed cost-effectiveness studies of novel pharmacological treatments (ezetimibe, proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors, omega-3 polyunsaturated fatty acids [n-3 PUFAs], and the cardiovascular polypill) compared with standard care for the secondary prevention of CVD. Methods We searched seven databases and the reference list of selected literature reviews for eligible cost-effective analyses (CEA) published between January 2009 and January 2020 that evaluated the above novel treatments versus standard care. Two independent reviewers performed the screening and evaluation in accordance with the Consolidated Health Economic Evaluation Reporting Standards statement. Cost results were adapted to 2018 US dollars (US$) to facilitate comparisons between studies. Consideration of cost-effectiveness was based on the original study criteria. Results Thirty-two studies were included in this review, most of them adopting a healthcare perspective. Studies evaluating ezetimibe, PCSK9 inhibitors and n-3 PUFAs assessed their addition to standard care compared with standard care alone, while studies analysing the polypill evaluated the replacement of multiple mono…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third, high prices for new treatments, such as PCSK9 inhibitors, have been identified as a barrier to swift coverage and reimbursement by insurers [21–24].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [21]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 76 · Cited by 34
Research works printed but not linked: 1
- Excellence NIfHaC. Guide to the methods of technology appraisal 2013. London: NICE; 2013 (Accessed 15 April 2020).
Metadata
- Authors
- Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z.
- Affiliations
- Monash University (AU)
- Corresponding author
- Ademi, Zanfina
- ORCID
- Venue
- PharmacoEconomics
- Published
- 2020-06-25
- Volume
- 38
- Issue
- 10
- Pages
- 1095-1113
- ISSN
- 1170-7690 (ISSN-L)
- 1179-2027
- OpenAlex
- W3037786329
- Semantic Scholar
- 2fa67444d8420cc8277b01c0b2f671d9c159fed3
- Cited by
- 34
- References
- 76
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 11 · 2021: 5 · 2020: 2
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- PharmacoEconomics (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- secondary prevention, cardiovascular disease, cost-effectiveness, ezetimibe, PCSK9 inhibitors, omega-3 polyunsaturated fatty acids, fixed-dose combination, lipid-lowering therapy, incremental cost-effectiveness ratio, healthcare perspective, cardiovascular risk reduction, statins, ezetimibe-simvastatin combination, LDL cholesterol lowering
- MeSH terms
- Proprotein Convertase 9, Anticholesteremic Agents, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. https://app.cochat.ai/papers/10.1007/s40273-020-00936-0
- The paper
- Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020). Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. PharmacoEconomics. https://doi.org/10.1007/s40273-020-00936-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.